Ultrastructural localization of the vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) receptor-2 (FLK-1, KDR) in normal mouse kidney and in the hyperpermeable vessels induced by VPF/VEGF-expressing tumors and adenoviral vectors

Citation
D. Feng et al., Ultrastructural localization of the vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) receptor-2 (FLK-1, KDR) in normal mouse kidney and in the hyperpermeable vessels induced by VPF/VEGF-expressing tumors and adenoviral vectors, J HIST CYTO, 48(4), 2000, pp. 545-555
Citations number
55
Categorie Soggetti
Medical Research Diagnosis & Treatment
Journal title
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY
ISSN journal
00221554 → ACNP
Volume
48
Issue
4
Year of publication
2000
Pages
545 - 555
Database
ISI
SICI code
0022-1554(200004)48:4<545:ULOTVP>2.0.ZU;2-U
Abstract
Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) interacts with two high-affinity tyrosine kinase receptors, VEGFR-1 and VEG FR-2, to increase microvascular permeability and induce angiogenesis. Both receptors are selectively expressed by vascular endothelial cells and are s trikingly increased in tumor vessels. We used a specific antibody to locali ze VEGFR-2 (FLK-1. KDR) in microvascular endothelium of normal mouse kidney s and in the microvessels induced by the TA3/St mammary tumor or by infecti on with an adenoviral vector engineered to express VPF/VEGF. A pre-embeddin g method was employed at the light and electron microscopic levels using ei ther nanogold or peroxidase as reporters. Equivalent staining was observed on both the luminal and abluminal surfaces of tumor- and adenovirus-induced vascular endothelium, but plasma membranes at interendothelial junctions w ere spared except at sites connected to vesiculovacuolar organelles (VVOs). VEGFR-2 was also localized to the membranes and stomatal diaphragms of som e VVOs. This staining distribution is consistent with a model in which VPF/ VEGF increases microvascular permeability by opening VVOs to allow the tran sendothelial cell passage of plasma and plasma proteins.